PSY 520 Exam 3 with precise detailed solutions

2



PSY 520 Exam 3 with precise detailed || || || || || || ||




solutions


Considerations for post-bariatric surgery || || ||




- increased gastric pH
|| || ||




- Decreased SA
|| ||




- impact on ER agents
|| || || ||




Elixir, is it desirable vehicle?
|| || || ||




Not desirable vehicle or base for pediatric pts b/c of alcohol content
|| || || || || || || || || || ||




Levigating agent ||




used to moisten and soften a tablet to facilitate the prep of liquid, especially when a large number
|| || || || || || || || || || || || || || || || || ||




of tablets is required or if tablets are extremely difficult to crush
|| || || || || || || || || || ||




General compounding methods/steps
|| ||




Trituration=> Levigation => mix to final volume => package and store || || || || || || || || || ||




Extemporaneous formulations resources || ||




- primary literature
|| ||




- package insert
|| ||

,2




- drug monographs
|| ||




- ASHP extemporaneous formulations book
|| || || ||




Benefits of standardizing concentrations
|| || ||




-Increased patient safety || ||




-Decreased health costs || ||




-Simplified ordering ||




-Allows for premixing || ||




-Reduced operational variations || ||




What meds are generally unsuitable for crushing
|| || || || || || ||




Atypical dosage form (sublingual, lozenge/buccal tablet, effervescent)
|| || || || || ||




Pharmacokinetic (PK) alteration (ER, etc.) || || || ||




Irritant (Risedronate, Ganciclovir, Everolimus)
|| || ||




Exposure risk (NIOSH list of antineoplastic and other healthcare drugs in healthcare settings)
|| || || || || || || || || || || ||




Unpalatable

,2




examples of drug types of pk alterations || || || || || ||




Extended-release formulations ||




Delayed-release formulations ||




Increased exposure ||




Release in specific area of the GI tract
|| || || || || || ||




Enhanced drug-delivery system || ||




Which med types are NOT always a complete contraindication
|| || || || || || || ||




Exposure risk, unpalatable || ||




Do not crush resources
|| || ||




- Drug monographs
|| ||




- Primary literature and other references
|| || || || ||




- Drug manufacturer information request
|| || || ||




- Institute for Safe Medication Practices (ISMP) Oral Dosage Forms That Should Not Be Crushed
|| || || || || || || || || || || || || || ||




– “ISMP Do Not Crush List”, last updated 2018 → no longer updated :(
|| || || || || || || || || || || || ||




Risks and considerations of manipulation and extemporaneous prep
|| || || || || || ||

, 2


Enteral tube administration compatibility
|| || ||




Variable doses ||




Contamination


Mixing solution compatibility || ||




*T or F. A med that can be crushed is automatically compatible for enteral tube administration
|| || || || || || || || || || || || || || || ||




and/or with tube feedings || || ||




False. Is NOT automatically compatible
|| || || ||




With enteral tubes _________ prep are generally preferred
|| || || || || || ||




liquid preps ||




What can lead to variable doses
|| || || || ||




- Improper or variable technique could lead to under- or over-dosing
|| || || || || || || || || ||




- Fragment or powder loss when crushing/splitting
|| || || || || ||




- Uneven splitting
|| ||




- Over-the-counter equipment available for splitting/crushing
|| || || || ||